GILD241018C79000
- 5.40
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Sticks to Its Buy Rating for Gilead Sciences (GILD)
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
Unusual Options Activity: HES, TSLA and Others Attract Market Bets, HES V/OI Ratio Reaches 103.1
EST Oct 11th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Morgan Stanley Remains a Hold on Gilead Sciences (GILD)
Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?
US stocks | Citigroup is optimistic! Norwegian cruise, Carnival cruise, and Royal Caribbean cruise hit new highs; Chip stocks continue to rise! Broadcom rose nearly 70% this year, hitting a historical high.
Bullish on by multiple institutions! Asset management company KKR & Co rose nearly 3% overnight, with an annual increase of over 60%.
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $100
Morgan Stanley raised the target price of gilead sciences to $100.
JPMorgan: Raised gilead sciences' target price from $95 to $100, maintaining a "shareholding" rating.
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
Gilead Sciences Is Maintained at Overweight by JP Morgan
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Raymond James Adjusts Gilead Sciences Price Target to $95 From $94
Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024